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Abstract
In  renal  transplant  recipients,  polyomavirus  BK  can  reactivate  resulting  in  graft 
nephropathy.  Screening for  BK virus  replication may allow for  earlier  intervention  with 
reduced allograft loss. The measurement of urinary cell BKV VP1 mRNA for identify viral 
replication levels at risk of developing nephropathy has been proposed. In this paper the  
development, optimization, and standardization of a Taqman Real-time RT-PCR assay for 
the quantitation of BKV VP1 mRNA levels in urine is described. Subsequently, the method 
has been validated on urine specimens obtained from renal transplant recipients. The use 
of VP1 mRNA measurement as a marker for viral replication and a tool for non invasive 
diagnosis  of  nephropathy  should  be regarded with  great  caution,  given the  potentially 
limited positive predictive value and the drawbacks associated with the complexity of the 
real-time RT-PCR assay requiring an expert well trained operator and the relatively poor 
cost-efficiency ratio. 
Key words
Polyomavirus BK; Real-time RT-PCR; VP1 mRNA; BK virus-associated nephropathy; 
renal transplantation.  
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1. Introduction
Human polyomavirus  BK (BKV) is a highly prevalent  virus characterized by latency in  
uroepithelial  cells  and  other  sites.  In  renal  transplantation,  in  the  context  of  intense 
immunosuppression,  BKV  can  reactivate  from  latency  resulting  in  BKV-associated 
nephropathy with  interstitial  nephritis and/or ureteral stenosis in 1-10% of the patients,  
leading to graft  failure and return in hemodialysis  in 30 up to 80% of the cases  (1-3). 
Screening for polyomavirus replication, by urine and serum viral load quantitation  (4,5), 
may allow for earlier intervention with reduced allograft loss (2). Ding et al.  (6) proposed 
the measurement of urinary cell BKV VP1 mRNA for identify viral replication levels at risk  
of  developing nephropathy.  Although there is no definitive cut-off  for  BKV VP1 mRNA 
levels diagnostic of nephropathy, Dadhania et al. (7) found that the median BKV VP1 copy 
number  in  renal  transplant  patients  with  BKV  replication  without  nephropathy  was 
significantly lower in comparison to that reported in renal allograft recipients with biopsy 
proven nephropathy (267 BKV VP1 copies/pg of total RNA vs. 34,000, p = 0.004). 
In this paper the development, optimization, and standardization of a Taqman Real-Time 
reverse transcription (RT)-PCR assay for the quantitation of BKV VP1 mRNA levels in 
urine is  described.  Subsequently,  the method has been validated on urine specimens 
obtained from renal transplant recipients.
3
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
1
2. Materials and methods
2.1 Clinical samples
Two-hundred-seventeen  urine  and  217  serum  specimens  from  114  renal  transplant 
recipients (61 males, 53 females; men age ± standard deviation, 56.9±9.7 years; range, 
29-77) were studied. The occurrence of BKV-associated nephropathy was diagnosed by 
histopathological evaluation on kidney graft biopsy, that was collected in the presence of 
renal  function  abnormalities and/or  on  the  basis  of  clinical  features  suggestive  of 
nehropathy and/or rejection. 
2.2 Nucleic acid extraction 
Automated extraction of total nucleic acids from urine samples was performed with the 
NucliSens easyMAG platform (bioMeriéux, Marcy l’Etoile, France). As regards total RNA, 
extracted specimens were subjected to RQ1 RNase-Free DNase digestion (Promega, 
Milan, Italy), following the manufacturer’s instruction. A second automated extraction was 
performed in order to remove the DNase buffer that could interfere with the amplification. 
The absence of contaminating DNA was ascertained by PCR amplification (see section 
2.3), following the second extraction, that tested negative. 
2.3 Real Time PCR for BKV-DNA quantitation in serum and urine samples
BKV DNA quantitation was performed by Real Time TaqMan PCR using a commercial kit  
(BKV Q-PCR Alert Kit; Nanogen Advanced Diagnostic, Milano, Italy) for the detection of 
the target viral gene encoding for the large T-antigen of BKV with the 7300 Real Time PCR 
System  (Applied  Biosystems,  Foster  City,  CA),  according  to  the  manufacturer’s 
instructions and as described previously (4). Briefly, PCR amplifications were set up in a 
reaction volume of 25 μl that contained 5 μl of extracted sample or negative control (sterile 
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double-distilled  H2O)  or  plasmid.  The  assay  is  linear  in  the  range  101-106 copies  per 
reaction, corresponding to an absolute quantitation of 103 copies/ml. 
2.4 Plasmids
The plasmid pBKV (ATCC 33-1 [ATCC, Manassas, VA]), containing the complete genome 
sequence of BKV (linearized using restriction enzyme BamHI) and cloned into the pBR322 
(Invitrogen, Carlsbad CA) vector, was used to determine the sensitivity and linear range of 
the PCR assay.  
The plasmid pGAPDH containing a fragment of 512 bp within the region between exon 6 
and 8 of  the housekeeping gene Glyceraldehyde-3-phosphate-dehydrogenase (GenBank 
accession  no.  J04038;  primer  F  5’-GCCAAAAGGGTCATCATCTC-3’;  primer  R  5’-
GGGGCCATCCACAGTCTTCT-3’;  probe  VIC-5’-TGGTATCGTGGAAGGA-3’-MGB 
designed using the Primer Express 3.0 software (Applied Biosystems) was cloned into 
pCR®2.1- TOPO-TA® cloning  (Invitrogen)  and  propagated  in  TOP10  high-efficiency 
chemically-competent cells (Invitrogen), according to the manufacturer’s instructions. 
2.5 cRNA standard production
A large amount of cRNA of the pBKV was obtained by using the T7 RiboMAX Express 
Large  Scale  RNA  Production  System  (Promega),  according  to  the  manufacturer’s 
instructions.  After   the  transcription,  the  DNA template  was  removed  by  adding  RQ1 
RNase-free DNase to a concentration of 1 U/μg DNA. After incubation at 37°C for 15 min., 
the  RNA  was  purified  by  performing  two  automated  extractions  with  the  NucliSens 
easyMAG instrument  (bioMeriéux).  The concentration  of  BKV-cRNA was  estimated by 
spectrophotometric reading at  OD260.  To determine the sensitivity of the RT-PCR assay, 
stock preparations of BKV-cRNA were diluted to 10-1 copies/μl by serial 10-fold dilutions. 
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To simulate the natural specimen, BKV-cRNA was extracted in parallel with the nucleic 
acid of the sample.
2.6 Reverse transcription 
The RT reaction was done  by a random cDNA syntesis from 10 µl of extracted sample 
RNA in two step: first a reaction mixture containing random primers (50 ng/ml)(Invitrogen)  
and 10 mM dNTPs (Invitrogen, Carlsbad, CA) was added and incubated at 65°C for 5 min.  
using the 9800 Fast Thermal Cycler (Applied Biosystems, Monza, Italy); subsequently, a 
second reaction mixture containing 0.1 M DTT, 10 x Buffer (200 nM Tris-HCl [pH 8.4], 500 
nM  KCl),  RNase  OUTTM (40  unit/µl)(Invitrogen)  and  reverse  transcriptase  (50  unit/µl)
(SuperScriptTM II RT, Invitrogen), giving a total volume 20 µl, was used. After incubation for  
10 min. at 25°C, 50 min. at 42°C and 15 min. at 70°C, the cDNA mixture was used as 
target cDNA. 
2.7 Optimization and standardization of the Real-time RT-PCR assay for BKV VP1 mRNA
Primers and probe for BKV VP1 mRNA were obtained from the literature (6) and were as 
follows:  primer  F  5’-TGCTGATATTTGTGGCCTGTTTACTA-3’;  primer  R  5’-
CTCAGGCGGATCTTAAAATATCTTG-3’;  probe  5’-FAM-
AGCTCTGGAACACAACAGTGGAGAGGCC-TAMRA-3’. For the optimization of the assay, 
various conditions that affect amplification were tested, such as concentrations of primers 
(0.12 mM; 0.5 mM; 0.9 mM) and probe (0.1 mM; 0.18 mM; 0.25 mM), and MgCl2 (3 mM; 4 
mM; 5 mM). Two µl of cDNA, retrotranscripted BKV-cRNA standard or negative control  
(sterile H2O) were added to 23 µl of a reaction mix containing 1X master mix (Invitrogen), 
primers and probe, giving a final volume of 25 µl. Amplification profile was optimized for  
the 7300 Real Time PCR System (Applied Biosystems), as described above. 
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The sensitivity of Real Time PCR assays is defined as the lowest concentration of target 
quantified at a frequency of 100%.  The dynamic range (or linearity rate) was evaluated 
using 10-fold dilutions (from 1010 to 100 copies/reaction) of BKV-cRNA standard. Precision 
or intra- and inter-assay variability (CV) was evaluated using different concentrations of  
standard BKV-cRNA (ranging from 105 to 102 copies/reaction) within a single run (n = 10) 
or  different  run  experiments  (n  =  10)  with  single  replicates  of  each  concentration 
considered  as  an  unknown  specimen.  The  primers  were  tested  for  potential  cross-
reactivity with  related viral sequences of polyomaviruses JC, SV40, KI and WU based on  
the data available at the BLAST alignment software. Similarly, BLAST was also performed 
on short fragments (primers lacking at the 3’end down to 15 nucleotides).
In  order  to  ascertain  the  identity  of  the  resulting  products  a  cycle  sequencing  was 
performed. PCR amplification products were used as templates for DNA sequencing using 
the  BigDye  Terminator  chemistry,  following  the  manufacturer’s  instructions  (BigDye 
Terminator  v3.1  Cycle  Sequencing  Kit  [Applied  Biosystems,  Warrington,  UK]).  Cycle 
sequencing was performed with the 9800 Fast Thermal cycler (Applied Biosystems) under 
the following conditions: an initial denaturation step of 1 min. at 96° C; 96°C for 10 sec.,  
50° C for 5 sec, 60° C for 4 min for twenty-five cycles. In order to purify the sequencing  
product  from not-incorporated BigDye  Terminators,  the mixture  was loaded direct  onto 
Centrisep  columns  (Applied  Biosystems).  Subsequently,  sequencing  products  were 
subjected  to  capillar  gel-electrophoresis  using  the  3130x1  Genetic  Analyzer  (Applied 
Biosystems).   
A  number  of  precautions  were  undertaken to  prevent  the  occurrence  of  false-positive 
results.  Each  RT-PCR  run  included  control  reactions  lacking  template  (no-template 
controls)  to  test  for  the  presence  of  contamination  or  the  generation  of  nonspecific 
amplification products under the assay conditions used. The optimization criteria for the 
Real Time PCR assay for the housekeeping gene GAPDH were the same of VP1 mRNA.
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2.8 Quantitation of the urine BKV VP1 mRNA level 
For Real-time RT-PCR quantitation, a standard curve was created in a  4-log range by 10-
fold  serial  dilutions  of  the  BKV-cRNA  and  pGAPDH.  Urine  VP1  mRNA  levels  were 
measured by normalizing the number of  mRNA copies on the basis  of  the number of 
urinary cells. This was achieved  by amplifying separately the housekeeping gene GAPDH 
(considering the linearity range of  the pGAPDH ranging from 102 to 105) and the viral 
target. In this study, a patient was classified as BKV replication positive if the urine VP1 
mRNA copy number was >103/103 cells. 
2.9 Statistical analysis
The  coefficient  of  variation  for  samples  quantified  in  repeated  measurements  was 
calculated. Descriptive statistics were expressed as absolute value and percentage. For 
statistical  analysis  the  t  test  was  used.  Operating  characteristics,  including  sensitivity, 
specificity,  negative  predictive  value  (NPV),  and  positive  predictive  value  (PPV)  were 
evaluated by using a commercially available software (MedCalc; version 9.2.1.0).
8
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
1
3. Results
3.1 Optimization, standardization, and validation of Real Time PCR assays
The following primer/probe and MgCl2 concentrations were chosen: 0.25 mM/0.18 mM and 
3 mM MgCl2, and 0.5 mM/0.25 mM and 3 mM MgCl2 for VP1 and GAPDH, respectively. 
The dynamic range of the home-made Real Time PCR for VP1 was evaluated by carrying 
out serial dilutions of BKV-cRNA (from 1010 to 100 copies/reaction), and ranged from 108 to 
102. The sensitivity of the assays was 10 copies/reaction. The precision, defined as the 
level  of  concordance  of  the  individual  test  results  within  a  single  round  (intra-assay 
precision)  and  from  one  run  to  another  (inter-assay  precision),  was  evaluated  using 
different  concentrations  of  BKV-cRNA,  ranging from 105 to  102 copies/reaction,  and is 
reported in Table 1.
3.2 Clinical samples
Results  are  summarized  in  Table  2.  Based  on  urine  VP1 mRNA measurement,  BKV 
replication  was  found  in  31/217  (14.3%)  specimens  from  20/114  (17.6%)  patients;  in 
particular, 15 specimens (6.9%) of 9 patients (7.9%) with levels >104 copies/103 cells and 5 
(2.3%) of 3 (2.6%) >105. As regards viremia and viruria, BKV-DNA resulted positive (above 
103 copies/ml) in 18 (8.3%9 and 23 (10.6%) serum and urine specimens, respectively from 
9 (7.9%) and 15 (13.2%) patients.  A histologically confirmed diagnosis of BKVAN was 
made in two patients, both with VP1 mRNA levels >105 (66.7% of patients above this cut-
off level) and with serum BKV-DNA >1 x 106 copies/ml (66.7% of patients above this cut-
off level). Urine VP1 mRNA was detected in all the cases, except five, in association to 
viremia  and  in  all  the  cases  to  viruria.  Considering  the  highest  level  in  each  patient,  
median urine VP1 mRNA level was 31236 copies/103 cells; no difference of VP1 mRNA 
levels was found between the two patients who developed BKVAN and the highest values 
9
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
1
in  patients  who  did  not  developed  BKVAN.  Operating  characteristics  of  VP1  mRNA 
measurement for levels >105 copies/103 cells were as follows: sensitivity 100%; specificity 
57.1%; positive predictive value 25%; negative predictive value 100%.
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4. Discussion
In this paper the optimization and standardization of a Real-time RT-PCR assay for the 
quantitation of urine VP1 mRNA levels is described. This method was first proposed by 
Ding et al.  (6) as a noninvasive and accurate tool for diagnosing BKVAN and has been 
used more recently to quantify BKV replication in monitoring renal transplant recipients,  
thus  possibly  representing  an  alternative  approach  to  serum  and  urine  viral  load 
measurement. However, as pointed out by Nickeleit et al. (8) and Hirsch (9), some factors 
could affect the relevance of VP1 mRNA quantitation, in particular the high susceptibility of  
the extraction of mRNA from urinary cells to erroneous results and the degree of viral 
genomic VP1 DNA contaminating the VP1 cDNA preparation, that could be overcome by 
the quantitation of VP1 signals after omitting reverse transcription or after prior DNase 
digestion. In the present study, the potential drawbacks associated to mRNA extraction 
have  been  overcome by performing  an  automated  extraction  of  total  nucleic  acids,  a 
DNase digestion of extracted specimens, and a second automated extraction to remove 
the DNase buffer that could interfere with the amplification. This procedure, by removing 
viral genomic VP1 DNA contaminating potentially the VP1 cDNA preparation, should allow 
for a more correct quantitation of BKV VP1 mRNA. 
The Real time RT- PCR assay for BKV VP1 mRNA designed by Ding et al. (6) target VP1, 
a major capsid protein responsible for the characteristics icosahedron feature and enabling 
BKV to entry into cells. This target was chosen because the transcription and translation of 
VP1 are contingent upon viral DNA replication, so that VP1 mRNA are detected only in  
infected productively cells. The design of primers and probe was made to target a highly 
conserved region of the VP1 region and incorporated multiple sequence mismatches with 
the polyomavirus JCV VP1 region. The assay was optimized by examining different primer 
and probe concentrations and was found to be very sensitive with a minimum cut-off for 
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detection of 10 copies/reaction.  The dynamic range was evaluated by carrying out serial 
dilutions of BKV-cRNA and ranged from 108 to 102. When increased sensitivity and broad 
dynamic range are combined, it is possible to quantify template from samples containing a 
wide range of concentrations, as in clinical samples. This avoids the need for dilution of 
the amplicon prior  to  conventional  detection or  repetition of  the assay using a diluted 
sample because the first result falls outside the detection limits. The assay reproducibility 
was high with a median intra-assay and inter-assay variability of  0.445% (range 0.31% to  
0.49%) and 1.98% (range 1.90% to 2.33%), respectively. 
To confirm the specificity of the resulting product and that the assay did not  cross-react 
with related viral sequences of polyomaviruses JC, SV40, KI and WU, the primer set was 
evaluated  by  the  BLAST  alignment  software  and  a  cycle  sequencing  of  the  PCR 
amplification product was performed.  
The assay has been validated subsequently on clinical specimens from a group of renal 
transplant recipients in which two case of confirmed nephropathy was diagnosed. The 
availability of  a reliable quantitative test permitted to evaluate different cut-off  levels in 
relation  to  the  presence  of  viral  replication  and  the  development  of  BKV-associated 
nephropathy. The identification of viral replication represents a tool to evaluate the risk of  
development of nephropathy, although high levels of viral replication may occur even in 
the absence of it (4). Polyomavirus BK replication occurs in the urothelial cells and results 
in shedding of urothelially derived decoy cells in high number and only replicating BKV 
leads to these cytopathic changes and the shedding of decoy cells in urine. In this study,  
the measurement of VP1 mRNA copies has been normalized on the basis of the number 
of  urinary cells,  rather  than on the amount  of  total  RNA. Because decoy cells  mostly  
contain BK virus antigens (9), it is likely that extracted mRNA originated from these cells. 
Therefore, the availability of a RT-PCR that normalized the measurement of  BKV VP1 
mRNA on the basis of the number of cells could be useful for investigating the relationship 
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between these findings and other markers of viral replication, such as urine cytology (i.e.  
decoy cells), viremia and viruria, in kidney transplant recipients at risk of BKV-associated 
nephropathy.  Nevertheless,  it  has  to  be  taken  into  account  that  the  use  of  the 
housekeeping gene GAPDH as quantification control might be affected by different factors 
such  as  treatments  and  biological  processes,  thus  potentially  influencing  its  role  in 
normalisation when considering severely altered or dead cells as shed renal tubular cells 
(10). Polyomaviruses replication may occur without clinical effects along the urothelium of  
healthy  individuals  and  kidney  allograft  recipients.  There  are  established  protocols  to 
screen for BKV-associated nephropathy, based on BKV-DNA detection by real time PCR 
in blood and urine  (4,11); these screening methods already provide a reliable basis for 
further treatment recommendation. Therefore, the use of VP1 mRNA measurement as a 
tool  for  non invasive  diagnosis of  nephropathy should be regarded with  great  caution, 
given the low prevalence of confirmed nephropathy in our study and the potentially limited 
positive predictive value, even considering high VP1 mRNA values, and the drawbacks 
associated with the complexity of the real-time RT-PCR assay requiring an expert well  
trained operator and the relatively poor cost-efficiency ratio. 
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Figure 1.  Dynamic range of BKV VP1 mRNA quantitation with  the Real-time RT-PCR 
assay. Number of cycle threshold (Ct) is plotted versus copy number (from 102 to 108). 
0
5
10
15
20
25
30
35
40
1,E+00 1,E+01 1,E+02 1,E+03 1,E+04 1,E+05 1,E+06 1,E+07 1,E+08
copy number
Ct
 v
al
ue
17
1
2
3
4
1
Table 1. Intra- and inter-assay variability of standard BKV-cRNA  by Real Time PCR.
 BKV-cRNA (copies/reaction) Intra-assay variability (%) Inter-assay variability (%)
102 0.49 2.33
103 0.48 1.97
104 0.41 1.90
105 0.31 1.99
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Table 2. Results of BKV VP1 mRNA measurements in renal transplant recipients. 
*Two (66.7%) with confirmed diagnosis of BKVAN.
Urine VP1 mRNA
(copies/103 cells)
Specimens N (%) 
Total = 217
Patients N(%) 
Total = 114
>103
>104
>105
      31 (14.3%) 
15 (6.9%) 
5 (2.3%) 
20 (17.6%) 
9 (7.9%) 
*3 (2.6%) 
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